CL2023000440A1 - Derivados de 1h-benzo[d]imidazol como inhibidores de tlr9 para el tratamiento de fibrosis - Google Patents

Derivados de 1h-benzo[d]imidazol como inhibidores de tlr9 para el tratamiento de fibrosis

Info

Publication number
CL2023000440A1
CL2023000440A1 CL2023000440A CL2023000440A CL2023000440A1 CL 2023000440 A1 CL2023000440 A1 CL 2023000440A1 CL 2023000440 A CL2023000440 A CL 2023000440A CL 2023000440 A CL2023000440 A CL 2023000440A CL 2023000440 A1 CL2023000440 A1 CL 2023000440A1
Authority
CL
Chile
Prior art keywords
fibrosis
benzo
treatment
imidazole derivatives
compounds
Prior art date
Application number
CL2023000440A
Other languages
English (en)
Spanish (es)
Inventor
Liu Chunjian
Regueiro-Ren Alicia
S Yoon David
Mandler Michael
L Posy Shoshana
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CL2023000440A1 publication Critical patent/CL2023000440A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL2023000440A 2020-08-19 2023-02-13 Derivados de 1h-benzo[d]imidazol como inhibidores de tlr9 para el tratamiento de fibrosis CL2023000440A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063067587P 2020-08-19 2020-08-19

Publications (1)

Publication Number Publication Date
CL2023000440A1 true CL2023000440A1 (es) 2023-07-28

Family

ID=77693625

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000440A CL2023000440A1 (es) 2020-08-19 2023-02-13 Derivados de 1h-benzo[d]imidazol como inhibidores de tlr9 para el tratamiento de fibrosis

Country Status (17)

Country Link
US (1) US12492188B2 (https=)
EP (1) EP4200292B1 (https=)
JP (1) JP2023538619A (https=)
KR (1) KR20230053645A (https=)
CN (1) CN116075510A (https=)
AR (1) AR123286A1 (https=)
AU (1) AU2021329323A1 (https=)
BR (1) BR112023002645A2 (https=)
CA (1) CA3189873A1 (https=)
CL (1) CL2023000440A1 (https=)
CO (1) CO2023001668A2 (https=)
ES (1) ES2999539T3 (https=)
IL (1) IL300702A (https=)
MX (1) MX2023001884A (https=)
PE (1) PE20230843A1 (https=)
TW (1) TW202227409A (https=)
WO (1) WO2022040260A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
MX2024009441A (es) * 2022-02-18 2024-08-14 Bristol Myers Squibb Co Compuestos de imidazopiridinilo sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9).
US20250163054A1 (en) * 2022-02-18 2025-05-22 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds useful as inhibitors of tlr9
CN117466863B (zh) * 2022-07-20 2026-03-24 盛睿泽华医药科技（苏州）有限公司 含芳香族取代基的苯并咪唑化合物及其制备方法和用途
WO2024102886A1 (en) * 2022-11-10 2024-05-16 Bristol-Myers Squibb Company Substituted benzimidazole compounds useful as inhibitors of tlr9
KR20250094727A (ko) * 2022-11-10 2025-06-25 브리스톨-마이어스 스큅 컴퍼니 Tlr9의 억제제로서 유용한 치환된 퀴놀론 화합물
WO2024163380A1 (en) * 2023-01-31 2024-08-08 Bristol-Myers Squibb Company Substituted benzimidazole compounds useful as inhibitors of tlr9

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1742637A4 (en) * 2004-04-23 2011-06-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
CA2648652A1 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
WO2013092467A1 (en) 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag 7-azaindole inhibitors of crac
US20130158066A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 4-azaindole inhibitors of crac
JP2015515472A (ja) * 2012-04-06 2015-05-28 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害薬
WO2013156431A1 (en) 2012-04-17 2013-10-24 Syngenta Participations Ag Pesticidally active pyridyl- and pyrimidyl- substituted thiazole and thiadiazole derivatives
EP2862853B1 (en) 2012-06-18 2020-01-22 Sumitomo Chemical Co., Ltd Fused heterocyclic compound
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
CN105992766A (zh) 2013-12-13 2016-10-05 武田药品工业株式会社 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物
AR107032A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
BR112019001270A2 (pt) 2016-07-30 2019-04-30 Bristol-Myers Squibb Company compostos indol substituídos com dimetoxifenila como inibidores de tlr7, tlr8 ou tlr9
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
US11370794B2 (en) * 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
JP7374772B2 (ja) 2017-07-05 2023-11-07 シンジェンタ パーティシペーションズ アーゲー 硫黄含有置換基を有する有害生物防除的に活性な複素環式誘導体
WO2019028302A1 (en) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS
KR102688509B1 (ko) 2017-08-04 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
JP7265554B2 (ja) 2017-11-14 2023-04-26 ブリストル－マイヤーズ スクイブ カンパニー 置換インドール化合物
KR102781141B1 (ko) 2017-12-15 2025-03-13 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 에테르 화합물
EA202091484A1 (ru) 2017-12-18 2021-03-25 Бристол-Маерс Сквибб Компани 4-азаиндольные соединения
MX2020005462A (es) 2017-12-19 2020-09-07 Bristol Myers Squibb Co Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).
WO2019126081A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
JP7304352B2 (ja) 2017-12-19 2023-07-06 ブリストル－マイヤーズ スクイブ カンパニー ６－アザインドール化合物
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
EP3728218B1 (en) 2017-12-20 2021-12-01 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
SG11202005733QA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds
WO2019136147A1 (en) * 2018-01-03 2019-07-11 The Board Of Trustees Of The University Of Illinois Toll-like receptor signaling inhibitors
AU2019319835A1 (en) 2018-08-08 2021-03-25 Bristol-Myers Squibb Company Indole and azaindole inhibitors of PAD enzymes

Also Published As

Publication number Publication date
EP4200292B1 (en) 2024-11-13
WO2022040260A1 (en) 2022-02-24
EP4200292A1 (en) 2023-06-28
CN116075510A (zh) 2023-05-05
TW202227409A (zh) 2022-07-16
KR20230053645A (ko) 2023-04-21
PE20230843A1 (es) 2023-05-23
US12492188B2 (en) 2025-12-09
CO2023001668A2 (es) 2023-03-17
MX2023001884A (es) 2023-03-10
JP2023538619A (ja) 2023-09-08
ES2999539T3 (en) 2025-02-26
US20230295122A1 (en) 2023-09-21
AU2021329323A1 (en) 2023-03-16
AR123286A1 (es) 2022-11-16
BR112023002645A2 (pt) 2023-04-04
IL300702A (en) 2023-04-01
CA3189873A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
CO2023001668A2 (es) Derivados de 1h-benzo[d]imidazol como inhibidores de tlr9 para el tratamiento de fibrosis
CO2024017733A2 (es) Inhibidores macrocíclicos de kras para el tratamiento de cáncer
JOP20220155A1 (ar) مشتقات البيرازول مفيدة كعوامل مضادة للسرطان
CO2022006858A2 (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
CL2017002207A1 (es) Inhibidores del factor beta de crecimiento de transformación (tgf-beta)
MX2021009276A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2.
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
PY1996328A (es) Compuestos de azalactam como inhibidores de hpk1
MX385838B (es) Derivados de 3-tetrazolil-bencen-1,2-disulfonamida como inhibidores de metalo-beta-lactamasa.
JOP20200130A1 (ar) مركبات كرومان مونوباكتام لعلاج العدوى البكتيرية
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
CO2023001670A2 (es) Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9
CL2022002148A1 (es) Inhibidores heterocíclicos de pad4
BR112022022452A2 (pt) Inibidores de il4i1 e métodos de uso
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2024002409A (es) Terapias contra el cancer.
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
MX2022011240A (es) Azálidos de urea inmunomoduladores.
CL2024001524A1 (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
CO2024002712A2 (es) Azálidos inmunomoduladores
DOP2023000088A (es) Derivados de pirazol como inhibidores de la ret-cinasa
UY39466A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis
EA202192107A1 (ru) Тритерпеноидные фунгициды для лечения грибковых костно-суставных инфекций